立方製藥(003020.SZ)：擬變更公司經營範圍
格隆匯 3 月 14日丨立方製藥(003020.SZ)公佈，公司於2021年3月13日召開第四屆董事會第九次會議，審議通過了《關於修改<合肥立方製藥股份有限公司章程>的議案》，同意公司因發展需要在原經營範圍基礎上增加部分內容，並對《公司章程》中相應條款進行修訂，具體內容如下：
變更前經營範圍：片劑、硬膠囊劑、顆粒劑、軟膏劑(含激素類)、小容量注射劑(含抗腫瘤類)、原料藥(多西他賽、非洛地平、二巰丁二酸、門冬氨酸鳥氨酸、佐芬普利鈣、甲磺酸多沙唑嗪、二巰丙磺鈉、丹皮酚、尿素、帕潘立酮、曲克蘆丁、羅氟司特、鹽酸哌甲酯)、凝膠劑、乳膏劑、中藥前處理、中藥飲片、提取車間、製藥機械、化工原料(不含危險品)的生產、銷售(在許可證有效期內經營)；藥品研發、技術轉讓；經營本企業自產產品的出口業務和本企業所需的機械設備、零配件、原輔材料的進口業務(國家限定除外)；功能性化粧品原料研發、生產、銷售、服務；醫藥中間體的生產、銷售；租賃。(依法須經批准的項目，經相關部門批准後方可開展經營活動)
變更後經營範圍：片劑、硬膠囊劑、顆粒劑、軟膏劑(含激素類)、小容量注射劑(含抗腫瘤類)、原料藥(多西他賽、非洛地平、二巰丁二酸、門冬氨酸鳥氨酸、佐芬普利鈣、甲磺酸多沙唑嗪、二巰丙磺鈉、丹皮酚、尿素、帕潘立酮、曲克蘆丁、羅氟司特、鹽酸哌甲酯)、凝膠劑、乳膏劑、滴眼劑、中藥前處理、中藥飲片、提取車間、制藥機械、化工原料(不含危險品)的生產、銷售(在許可證有效期內經營)；藥品研發、技術轉讓；經營本企業自產產品的出口業務和本企業所需的機械設備、零配件、原輔材料的進口業務(國家限定除外)；功能性化粧品原料研發、生產、銷售、服務；醫藥中間體的生產、銷售；租賃；自營和代理各類商品及技術的進出口業務(國家規定的專營進出口商品和國家禁止進出口的特殊商品除外)。(依法須經批准的項目，經相關部門批准後方可開展經營活動)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
